Johnson & Johnson (JNJ) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
JNJ's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
JNJ Revenue Analysis (2013–2024)
As of March 1, 2026, Johnson & Johnson (JNJ) generated trailing twelve-month (TTM) revenue of $92.15 billion, reflecting solid growth of +6.8% year-over-year. The most recent quarter (Q3 2025) recorded $23.99 billion in revenue, up 1.1% sequentially.
Looking at the longer-term picture, JNJ's 5-year compound annual growth rate (CAGR) stands at +1.6%, indicating moderate growth over time. The company achieved its highest annual revenue of $88.82 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows JNJ's business is primarily driven by Innovative Medicine (64%), and MedTech (36%). With over half of revenue concentrated in Innovative Medicine, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LLY (+45.4% YoY), AZN (+8.6% YoY), and BMY (+1.3% YoY), JNJ has underperformed the peer group in terms of revenue growth. Compare JNJ vs LLY →
Peer Comparison
Compare JNJ's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| JNJCurrent | $92.1B | +6.8% | +1.6% | 24.9% | |
| LLY | $45.0B | +45.4% | +15.1% | 38.9% | |
| AZN | $58.7B | +8.6% | +17.2% | 23.4% | |
| BMY | $48.3B | +1.3% | +13.1% | 20.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $88.82B | +4.3% | $61.35B | 69.1% | $22.15B | 24.9% |
| 2023 | $85.16B | +6.5% | $58.61B | 68.8% | $23.41B | 27.5% |
| 2022 | $79.99B | +1.6% | $55.39B | 69.3% | $21.01B | 26.3% |
| 2021 | $78.74B | -4.7% | $55.34B | 70.3% | $20.94B | 26.6% |
| 2020 | $82.58B | +0.6% | $54.16B | 65.6% | $19.73B | 23.9% |
| 2019 | $82.06B | +0.6% | $54.50B | 66.4% | $20.97B | 25.6% |
| 2018 | $81.58B | +6.7% | $54.49B | 66.8% | $21.18B | 26.0% |
| 2017 | $76.45B | +6.3% | $51.01B | 66.7% | $18.90B | 24.7% |
| 2016 | $71.89B | +2.6% | $50.10B | 69.7% | $20.89B | 29.1% |
| 2015 | $70.07B | -5.7% | $48.54B | 69.3% | $18.29B | 26.1% |
See JNJ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JNJ Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare JNJ vs AGIO
See how JNJ stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is JNJ's revenue growth accelerating or slowing?
JNJ maintains +6.8% revenue growth, in line with its 5-year CAGR of +1.6%. TTM revenue stands at $92.1B. Growth rate remains consistent with historical average.
What is JNJ's long-term revenue growth rate?
Johnson & Johnson's 5-year revenue CAGR of +1.6% reflects the sustained expansion pattern. Current YoY growth of +6.8% is near this long-term average.
How is JNJ's revenue distributed by segment?
JNJ reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.